NGS-dataset of putative driver mutations associated with benign peritoneal strumosis
Michael Brockmann,
Verena Schildgen,
Oliver Schildgen,
Jessica Lüsebrink,
Monika Pieper,
Alexandru Gudima
Affiliations
Michael Brockmann
Kliniken der Stadt Köln gGmbH, Klinikum der Privaten Universität Witten/Herdecke, Institut für Pathologie, Ostmerheimer Str. 200, D-51109 Cologne, Germany
Verena Schildgen
Kliniken der Stadt Köln gGmbH, Klinikum der Privaten Universität Witten/Herdecke, Institut für Pathologie, Ostmerheimer Str. 200, D-51109 Cologne, Germany
Oliver Schildgen
Kliniken der Stadt Köln gGmbH, Klinikum der Privaten Universität Witten/Herdecke, Institut für Pathologie, Ostmerheimer Str. 200, D-51109 Cologne, Germany; Corresponding author.
Jessica Lüsebrink
Kliniken der Stadt Köln gGmbH, Klinikum der Privaten Universität Witten/Herdecke, Institut für Pathologie, Ostmerheimer Str. 200, D-51109 Cologne, Germany
Monika Pieper
Kliniken der Stadt Köln gGmbH, Klinikum der Privaten Universität Witten/Herdecke, Institut für Pathologie, Ostmerheimer Str. 200, D-51109 Cologne, Germany
Alexandru Gudima
IMSP Institutul Oncologic din Republica Moldova, Sectia Ginecologie nr.2, str. N. Testemitanu 30, MD-2025 Chisinau, Republic of Moldova
A rare case of benign peritoneal strumosis was screened for driver mutations in genes relevant to currently approved cancer therapies. Therefore, three formalin fixed paraffin embedded issue sections were screened with the GeneReader Actionable Insights NGS panel (Qiagen, Hilden, Germany) for the occurrence of driver mutations. Several mutations were identified in drug-targetable genes, such as ALK, EGFR, and BRAF. The majority of identified mutations were single nucleotide variant, but also a insertion/deletion mutation was identified. The presented dataset is the first NGS dataset available from a patient with benign peritoneal strumosis.
